Advertisement
Screener

Oncotelic Therapeutics, Inc. (OTLC) Stockholders' Equity Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

Oncotelic Therapeutics, Inc. Stockholders' Equity Attributable to Noncontrolling Interest

Oncotelic Therapeutics, Inc. (OTLC) had Stockholders' Equity Attributable to Noncontrolling Interest of -$1.12 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest

us-gaap:MinorityInterest · last filed 2026-08-13

  • 2026-06-30: Stockholders' Equity Attributable to Noncontrolling Interest -$1.12M.
  • 2026-03-31: Stockholders' Equity Attributable to Noncontrolling Interest -$1.07M.
  • 2025-12-31: Stockholders' Equity Attributable to Noncontrolling Interest -$1.03M.
  • 2025-09-30: Stockholders' Equity Attributable to Noncontrolling Interest -$974.08K.
Period endStockholders' Equity Attributable to Noncontrolling Interest
2026-06-30-$1.12M
10-Q · filed 2026-08-13
2026-03-31-$1.07M
10-Q · filed 2026-05-14
2025-12-31-$1.03M
10-Q · filed 2026-08-13
2025-09-30-$974.08K
10-Q · filed 2025-11-17
2025-06-30-$907.07K
10-Q · filed 2025-08-13
2025-03-31-$839.67K
10-Q · filed 2025-05-15
2024-12-31-$774.12K
10-K · filed 2026-04-15
2024-09-30-$720.59K
10-Q · filed 2024-11-19
2024-06-30-$653.43K
10-Q · filed 2024-08-14
2024-03-31-$585.09K
10-Q · filed 2024-05-15
2023-12-31-$518.59K
10-K · filed 2025-04-15
2023-09-30-$463.50K
10-Q · filed 2023-11-14
2023-06-30-$389.25K
10-Q · filed 2023-08-18
2023-03-31-$296.25K
10-Q · filed 2023-05-22
2022-12-31-$215.62K
10-K · filed 2024-04-12
2022-09-30-$160.71K
10-Q · filed 2022-11-18
2022-06-30-$79.21K
10-Q · filed 2022-08-22
2022-03-31-$37.78K
10-Q · filed 2022-05-23
2021-12-31$202.76K
10-K/A · filed 2023-04-20
2021-09-30$379.71K
10-Q · filed 2021-11-22
2021-06-30$672.71K
10-Q · filed 2021-08-20
2021-03-31$1.01M
10-Q · filed 2021-05-24
2020-12-31$708.95K
10-K · filed 2022-04-15
2020-09-30$979.54K
10-Q · filed 2020-11-16